Johnson & Johnson (XSWX:JNJ)
CHF 205.1 -3.8 (-1.82%) Market Cap: 494.51 Bil Enterprise Value: 521.16 Bil PE Ratio: 29.35 PB Ratio: 7.52 GF Score: 76/100

Johnson & Johnson at Bank of America Global Healthcare Conference Transcript

May 12, 2026 / 06:20PM GMT
Release Date Price: CHF175.75 (+1.59%)
Jason Gerberry
Bofa Merrill Lynch Asset Holdings Inc - Analyst

For the next company presentation at the B of A Annual Healthcare Conference, my name is Jason Gerberry. I cover pharma and biotech at B of A, and I'm pleased to be moderating our next fireside discussion with Johnson & Johnson and John Reed, Executive Vice President, Pharma R&D. So, John, thanks so much for joining us.

John Reed
Johnson & Johnson - Executive Vice President - Pharmaceuticals, R&D

Great to be here. Looking forward to the chat.

Questions & Answers

Jason Gerberry
Bofa Merrill Lynch Asset Holdings Inc - Analyst

Well, look, as a company, I've had a lot of momentum, I think, in the R&D organization. So.

Looking forward to just maybe had a high level framing first, where you're at in terms of the pipeline and BD consideration versus in-house developed, you guys have shown a propensity, obviously, to have success on both fronts. And I imagine you're always opportunistically looking for best science,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot